MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
CRISPR Therapeutics AG Operating Expenses 2011-2026 | CRSP
Annual Operating Expenses CRISPR Therapeutics AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 668 M | 504 M | 594 M | 674 M | 541 M | 355 M | 243 M | 162 M | 106 M | 73.3 M | 26 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 674 M | 26 M | 359 M |
Quarterly Operating Expenses CRISPR Therapeutics AG
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 133 M | 230 M | 149 M | - | 111 M | 152 M | 141 M | - | 132 M | 165 M | 164 M | - | 182 M | 183 M | 177 M | - | 130 M | 138 M | 115 M | 108 M | 92.5 M | 80.7 M | 73.7 M | 66 M | 72.8 M | 55.3 M | 48.8 M | 45.3 M | 50 M | 38.4 M | 28.4 M | 31.4 M | 26 M | 24.9 M | 23.4 M | 27.7 M | 16.2 M | 17.4 M | 12.1 M | 12.4 M | 6.2 M | 3.62 M | 3.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 230 M | 3.62 M | 83.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 28.91 | 4.94 % | $ 1.4 B |  USA |
 |
Amarin Corporation plc
AMRN
|
233 M | $ 15.03 | 1.14 % | $ 6.13 B |  Irlanda |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
argenx SE
ARGX
|
2.27 B | $ 836.13 | 0.31 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 4.14 | 5.61 % | $ 353 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.78 | -8.44 % | $ 4.25 M | China |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
5.39 B | $ 198.18 | 1.37 % | $ 29 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.47 | -1.12 % | $ 8.35 B |  Australia |
 |
Bristol-Myers Squibb Company
BMY
|
12.2 B | $ 60.84 | 1.64 % | $ 124 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 106.92 | 1.1 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 217.6 | -0.23 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
189 M | $ 40.32 | 5.15 % | $ 4.16 B | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.41 | 2.32 % | $ 360 M | Britain |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.35 | 0.54 % | $ 1.51 B | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
539 M | $ 14.93 | 2.02 % | $ 4.61 B | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |